Understanding how a xenobiotic is metabolized, distributed, and eliminated is often critical to an appreciation of the toxic effect(s) of the compound. Further, extrapolation of results from animal testing to possible human health effects requires knowledge of metabolic pathways. The fidelity of the extrapolation is enhanced if the fate of a xenobiotic is known for both (all) species used in the extrapolation. Investigation of the mechanistic aspects of metabolic processes allows greater understanding of how metabolism of a xenobiotic might lead either to detoxification or to a reactive metabolite with greater toxicity. As more is learned about mechanisms of metabolism, more accurate predictions of the possible metabolic pathways for new compounds should be possible. This group carried out studies on 1.2.3.-trichloropropane (TCP), saligenin cyclic o-tolyl phosphate (SCOTP), cyclohexanone oxime (CHOX) and furan in the past year. As part of our continuing study on the metabolism of TCP, an industrial solvent, we have identified 2-(S-gluthathionyl) malonic acid as a biliary metabolite. This metabolite could arise by a series of oxidations and episulfonium ion intermediates and points out the potential reactivity of this compound. The male reproductive toxicity of tri o- cresyl phosphate may be attributed to the metabolic formation of SCOTP. In a recently completed study to determine the in vivo half-life of this reactive compound, the blood half-life of SCOTP was found to be long enough to be formed in the liver and transported to the testes--the target tissue. CHOX was readily absorbed, distributed and eliminated after a single oral dose of 1, 10 or 30 mg/kg. The majority of the radioactivity was eliminated in 24 hr. Pharmacokinetic studies have shown that CHOX has a biological half life of less than 1 hr. Only 4-5% of a dermally administered dose was absorbed. Oral administration of furan decreased hepatic P-450 content and the activity of P-450-dependent enzymes. Metabolism dependent covalent binding of furan to microsomal protein indicates that P-450 IIE1 preferentially catalyzes the metabolic activation of furan.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES021075-07
Application #
3876846
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Lo, Yi-Ching; Liu, Yuxin; Lin, Yi-Chin et al. (2008) Neuronal effects of 4-t-Butylcatechol: a model for catechol-containing antioxidants. Toxicol Appl Pharmacol 228:247-55
Clayton, Natasha P; Yoshizawa, Katsuhiko; Kissling, Grace E et al. (2007) Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp Toxicol Pathol 58:223-36
Ferguson, Ling-Jen Chen; Lebetkin, Edward H; Lih, Fred B et al. (2007) 14C-labeled pulegone and metabolites binding to alpha2u-globulin in kidneys of male F-344 rats. J Toxicol Environ Health A 70:1416-23
Garner, C E; Sumner, S C J; Davis, J G et al. (2006) Metabolism and disposition of 1-bromopropane in rats and mice following inhalation or intravenous administration. Toxicol Appl Pharmacol 215:23-36
Chen, Ling-Jen; DeRose, Eugene F; Burka, Leo T (2006) Metabolism of furans in vitro: ipomeanine and 4-ipomeanol. Chem Res Toxicol 19:1320-9
Sanders, J M; Chen, L-J; Lebetkin, E H et al. (2006) Metabolism and disposition of 2,2',4,4'- tetrabromodiphenyl ether following administration of single or multiple doses to rats and mice. Xenobiotica 36:103-17
Chen, L-J; Lebetkin, E H; Sanders, J M et al. (2006) Metabolism and disposition of 2,2',4,4',5-pentabromodiphenyl ether (BDE99) following a single or repeated administration to rats or mice. Xenobiotica 36:515-34
Sanders, J M; Lebetkin, E H; Chen, L-J et al. (2006) Disposition of 2,2',4,4',5,5'-hexabromodiphenyl ether (BDE153) and its interaction with other polybrominated diphenyl ethers (PBDEs) in rodents. Xenobiotica 36:824-37
Mathews, James M; Etheridge, Amy S; Valentine, John L et al. (2005) Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 33:1555-63
Irwin, Richard D; Parker, Joel S; Lobenhofer, Edward K et al. (2005) Transcriptional profiling of the left and median liver lobes of male f344/n rats following exposure to acetaminophen. Toxicol Pathol 33:111-7

Showing the most recent 10 out of 30 publications